
June Jobs Report OK, But Waiting For The Other Shoe To Drop
The American job market exceeded expectations in June, posting job gains of 147,000 and seeing the unemployment rate tick down by a tenth of a point to 4.1%.
All in all, it's an acceptable report, but not without its flaws – some conditional and some fundamental – which must be taken into account.
For example, why did the unemployment rate fall? One would think it's due to more people finding jobs, but in this case, just the opposite is true. The civilian labor force – the number of people working and/or looking for work – shrank by 130,000. That's a lot of people who have just given up looking for work. When that happens and all else stays the same, the rate falls.
Another thing we should keep watching is the labor force participation rate, which dropped from 62.4% to 62.3%, not alarming, but from 62.6% a year ago, a drop considered notable.
Along racial and ethnic lines, the data shows inequity. Unemployment among whites is 3.6%, among Asians it's 3.5%, among Hispanics it's 4.8%, and among African-Americans it has ballooned to 6.8%.
The distribution of the job gains is troubling for the second straight month. Of the 147,000 jobs created in June, 73,000 – half – came in the government sector. Another 39,000 came in health care and 19,000 came in social assistance. Among the three sectors, 89% of June's job growth occurred. The other eight sectors showed little or no growth or actual losses. Uneven growth is vulnerable.
Further, that 73,000 figure for government jobs seems inordinately, curiously high. Given the intense activity of DOGE earlier in the year – layoffs, closings, etc. – and all the subsequent appeals and reversals, this is questionable at best.
All in all, what appears to be an OK job report is shaky and suspicious, and will be tested in the upcoming months.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 minutes ago
- Yahoo
Gas prices in Massachusetts declined from last week: Find out how much.
State gas prices declined last week and reached an average of $3.02 per gallon of regular fuel on Monday, down from last week's price of $3.07 per gallon, according to the U.S. Energy Information Administration. The average fuel price in state rose about 7 cents since last month. According to the EIA, gas prices across the state in the last year have been as low as $2.88 on April 14, 2025, and as high as $3.50 on July 8, 2024. A year ago, the average gas price in Massachusetts was 14% higher at $3.50 per gallon. >> INTERACTIVE: See how your area's gas prices have changed over the years at . The average gas price in the United States last week was $3.16, making prices in the state about 4.5% lower than the nation's average. The average national gas price is lower than last week's average of $3.21 per gallon. The USA TODAY Network is publishing localized versions of this story on its news sites across the country, generated with data from the U.S. Energy Information Administration. Please leave any feedback or corrections for this story here. This story was written by Ozge Terzioglu. Our News Automation and AI team would like to hear from you. Take this survey and share your thoughts with us. This article originally appeared on Standard-Times: Massachusetts gas prices declined from last week: See how much here
Yahoo
9 minutes ago
- Yahoo
Morgan Stanley Raises PT on Apellis Pharmaceuticals (APLS) to $26, Keeps a Hold Rating
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. On July 1, analyst Judah Frommer from Morgan Stanley raised the firm's price target on Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) to $26.00 from $25.00 while maintaining a Hold rating on the stock. Frommer attributed the rating to the company's market position and recent financial strategies. A biomedical scientist in a lab coat conducting research on biopharmaceutical compounds. He cited the company's significant royalty purchase agreement with Sobi, securing up to $300 million and including a $275 million upfront payment, stating that it would slash Sobi's royalty obligations on Aspaveli sales by 90%. This would result in immediate financial benefits for Apellis and may even ease investor concerns regarding the company's profitability. Despite this positive development, Frommer maintained a cautious outlook for Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) due to its future prospects. He stated that while the anticipated regulatory decisions from the FDA and CHMP and the launches of Empaveli/Aspaveli in new indications are significant events, they bring in as much uncertainty as confidence in the company's market potential. Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is a commercial-stage biopharmaceutical company that discovers, develops, and commercializes novel therapeutic compounds for treating diseases with unmet needs. Its product portfolio primarily includes EMPAVELI and SYFOVRE. SYFOVRE treats geographic atrophy secondary to age-related macular degeneration (GA), while EMPAVELI treats paroxysmal nocturnal hemoglobinuria (PNH). While we acknowledge the potential of APLS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Bloomberg
9 minutes ago
- Bloomberg
South Korea Seeks US Trade Deadline Extension as Tariffs Loom
South Korean and US trade officials have discussed extending the July 9 deadline for trade deals in a last-minute bid to avert sweeping tariffs from President Donald Trump. South Korean Trade Minister Yeo Han-koo held talks with US Trade Representative Jamieson Greer on Saturday in Washington, where he proposed manufacturing partnerships and called for the elimination or reduction of tariffs on products such as automobiles and steel, Seoul's industry ministry said in a statement on Sunday.